Gold Wrote: “I thought the information on the gastric cancers recently released was new information. Upon review of past filings, I find that to not be the case. This is very old information that has been known since April of 2004. The Japanese just finally got it in a scientific journal.”
Actually this is not correct. The initial results were only based on 23 cancers and 22 normal samples. Whereas, the newly published results were based on 47 cancers and 61 normal/benign tissues. The previous results were obviously the result of an ongoing study.
You might note that the level of sensitivity dropped a from 82% to 73%, but that the specificity increased from 95% to 97% (in spite of including benign cancers).
However the study had a relatively poor return of a relatively rare form called signet ring cell carcinoma. I called the BOCX to ask about this and they said that without the ring cell cancers, sensitivity would have come in around 80% or IOW consistent with previous results.
Study results published:
“On the other hand, the staining intensity of signet ring cell carcinoma was significantly weaker than that of the three adenocarcinoma groups.”
2004 study results:
“The study comprised 23 stomach cancer and 22 normal tissue samples. The Histo-RECAFTM test detected 82.6% of cancers with a specificity of 95.5%.”
2006 study results:
“The results indicate that RECAF was expressed in 34 out of 47 cancers and not expressed in 59 out of 61 normal or benign tissues.
This paper reports 73% sensitivity with 97% specificity using Histo-RECAF for tissue examination”
News 
Market Data 
Discover 
